In this regard, several vulnerabilities have been reported that enhanced sensitivity of SMARCA4-mutant lung cancers such as inhibition of Aurora kinase A10, CDK4/611, EZH212, ATR13, and KDM6 methyltransferase 14. This evidence concerns the gene SMARCA4 and lung carcinoma.